Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults with HIV (INSTINCT/GESIDA10918 Study)

View Full Paper

Ask AI

Bookmark

No significant differences in inflammatory biomarkers were observed between the two ART groups after 96 weeks.
Participants maintained virological suppression with over 95% success while switching regimens showed comparable weight changes.
This phase IV trial utilized a multicenter, open-label design with adults on stable ART for evaluation.
Equivalent profiles for systemic inflammation and metabolic outcomes were noted between BIC/FTC/TAF and DTG/3TC.

Discussion

No takes yet. Share an insight, caveat, or question.

Randomized trial compares inflammation and metabolic health in adults with HIV, suggesting similar outcomes for two drug regimens.

Serrano‐Villar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark